Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
B Acute Lymphoblastic Leukemia
Drug:
Asparlas (calaspargase pegol-mknl)
(
Asparagine depleter
,
Aspartate-ammonia ligase inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
FDA
Published date:
11/29/2023
Excerpt:
ASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.